Xiaoting Zhu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Xiaoting Zhu has a total of 23 co-authors. Here are the top co-authors by number of shared publications:
- Mingquan Li
Department of Neurology, The Third Affiliated Clinical Hospital of Changchun University of Chinese Medicine, China
3 shared publications - Jiale Wang
Traditional Chinese Medicine Department
2 shared publications - Yuhui Li
School of Chinese Medicine
2 shared publications Chengyan Wang
Changchun University of Traditional Chinese Medicine, Changchun, China
1 shared publication- Chunmei Dai
Changchun University of Traditional Chinese Medicine, Changchun, China
1 shared publication Cong Li
Changchun University of Traditional Chinese Medicine, Changchun, China
1 shared publication
Latest Publications
- Open Access
- 27 February 2026
- Published by Wolters Kluwer Health in Medicine
- Vol. 105 (9) , e47842
Causal relationship between obesity and diabetic neuropathy: A 2-sample Mendelian randomization study
A growing body of evidence suggests a potential correlation between obesity and diabetic neuropathy (DN), but the causal nature of this relationship remains uncertain. We conducted a Mendelian randomization (MR) analysis to investigate the causal relationship between obesity and DN. Independent single nucleotide polymorphisms strongly associated with DN were identified from genome-wide association studies. Summary statistics for body mass index (BMI), waist circumference (WC), hip circumference (HC), and waist-to-hip ratio (WHR) were also obtained from genome-wide association studies datasets. The causal effects were estimated using inverse-variance weighted analysis, MR-Egger regression, and weighted median estimation. Sensitivity analyzes were performed to assess the robustness of the findings. Inverse-variance weighted analysis revealed significant negative associations of BMI ( P = .0006, OR = 0.809, 95% CI: 0.716–0.913), WC ( P = .008, OR = 0.792, 95% CI: 0.665–0.943), and HC ( P = .032, OR = 0.871, 95% CI: 0.768–0.988) with DN risk. No significant association was observed for WHR ( P = .425, OR = 0.954, 95% CI: 0.849–1.071). After Bonferroni correction (α = 0.0125), there was a statistically significant relationship between BMI and DN ( P ≤ .0125), indicating a causal relationship. However, the causal relationships between WC, HC, WHR, and DN were not statistically significant, with P -values all > .0125. However, the OR value of MR analysis is close to 1, indicating that BMI may have a slight protective effect on the risk of DN.
- 27 February 2026
- Published by Wolters Kluwer Health in Medicine
- Vol. 105 (9) , e47842
Open AccessCausal relationship between obesity and diabetic neuropathy: A 2-sample Mendelian randomization study
A growing body of evidence suggests a potential correlation between obesity and diabetic neuropathy (DN), but the causal nature of this relationship remains uncertain. We conducted a Mendelian randomization (MR) analysis to investigate the causal relationship between obesity and DN. Independent single nucleotide polymorphisms strongly associated with DN were identified from genome-wide association studies. Summary statistics for body mass index (BMI), waist circumference (WC), hip circumference (HC), and waist-to-hip ratio (WHR) were also obtained from genome-wide association studies datasets. The causal effects were estimated using inverse-variance weighted analysis, MR-Egger regression, and weighted median estimation. Sensitivity analyzes were performed to assess the robustness of the findings. Inverse-variance weighted analysis revealed significant negative associations of BMI ( P = .0006, OR = 0.809, 95% CI: 0.716–0.913), WC ( P = .008, OR = 0.792, 95% CI: 0.665–0.943), and HC ( P = .032, OR = 0.871, 95% CI: 0.768–0.988) with DN risk. No significant association was observed for WHR ( P = .425, OR = 0.954, 95% CI: 0.849–1.071). After Bonferroni correction (α = 0.0125), there was a statistically significant relationship between BMI and DN ( P ≤ .0125), indicating a causal relationship. However, the causal relationships between WC, HC, WHR, and DN were not statistically significant, with P -values all > .0125. However, the OR value of MR analysis is close to 1, indicating that BMI may have a slight protective effect on the risk of DN.
- Open Access
- 1 January 2026
- Published by XMLink in Yonsei Medical Journal
- Vol. 67
Noninvasive Prediction of Silent Brain Infarction in Diabetic Foot: Performance and Utility of the DF-SBI-M3 Model
- 1 January 2026
- Published by XMLink in Yonsei Medical Journal
- Vol. 67
Open AccessNoninvasive Prediction of Silent Brain Infarction in Diabetic Foot: Performance and Utility of the DF-SBI-M3 Model
- 3 April 2024
- Published by Springer Nature
- p. 420-430
Comparisonof Chinese College Students’Anxiety During and BeforeCOVID19 Pandemic Based on Clustering Algorithm
- 3 April 2024
- Published by Springer Nature
- p. 420-430
Comparisonof Chinese College Students’Anxiety During and BeforeCOVID19 Pandemic Based on Clustering Algorithm
- Open Access
- 31 July 2022
- Published by Wiley in Evidence-Based Complementary and Alternative Medicine
- Vol. 2022, 1-19
Jiedu-Yizhi Formula Alleviates Neuroinflammation in AD Rats by Modulating the Gut Microbiota
Background. The Jiedu-Yizhi formula (JDYZF) is a Chinese herbal prescription used to treat Alzheimers disease (AD). It was previously confirmed that JDYZF can inhibit the expression of pyroptosis-related proteins in the hippocampus of AD rats and inhibit gut inflammation in AD rats. Therefore, it is hypothesized that JDYZF has a regulatory effect on the gut microbiota. Methods. In this study, an AD rat model was prepared by bilateral hippocampal injection of Aβ25-35 and AD rats received high, medium, and low doses of JDYZF orally for 8 weeks. The body weights of the AD rats were observed to assess the effect of JDYZF. The 16S rRNA sequencing technique was used to study the regulation of the gut microbiota by JDYZF in AD rats. Immunohistochemical staining was used to observe the expression levels of Caspase-1 and Caspase-11 in the hippocampus. Results. JDYZF reduced body weight in AD rats, and this effect may be related to JDYZF regulating body-weight-related gut microbes. The 16S rRNA analysis showed that JDYZF increased the diversity of the gut microbiota in AD rats. At the phylum level, JDYZF increased the abundances of Bacteroidota and Actinobacteriota and decreased the abundances of Firmicutes, Campilobacterota, and Desulfobacterota. At the genus level, the abundances of Lactobacillus, Prevotella, Bacteroides, Christensenellaceae_R-7_group, Rikenellaceae_RC9_gut_group, and Blautia were increased and the abundances of Lachnospiraceae-NK4A136-group, Anaerobiospirillum, Turicibacter, Oscillibacter, Desulfovibrio, Helicobacter, and Intestinimonas were decreased. At the species level, the abundances of Lactobacillus johnsonii, Lactobacillus reuteri, and Lactobacillus faecis were increased and the abundances of Helicobacter rodentium and Ruminococcus_sp_N15.MGS-57 were decreased. Immunohistochemistry showed that JDYZF reduced the levels of Caspase-1- and Caspase-11-positive staining. Conclusion. JDYZF has a regulatory effect on the gut microbiota of AD rats, which may represent the basis for the anti-inflammatory effect of JDYZF.
- 31 July 2022
- Published by Wiley in Evidence-Based Complementary and Alternative Medicine
- Vol. 2022, 1-19
Open AccessJiedu-Yizhi Formula Alleviates Neuroinflammation in AD Rats by Modulating the Gut Microbiota
Background. The Jiedu-Yizhi formula (JDYZF) is a Chinese herbal prescription used to treat Alzheimers disease (AD). It was previously confirmed that JDYZF can inhibit the expression of pyroptosis-related proteins in the hippocampus of AD rats and inhibit gut inflammation in AD rats. Therefore, it is hypothesized that JDYZF has a regulatory effect on the gut microbiota. Methods. In this study, an AD rat model was prepared by bilateral hippocampal injection of Aβ25-35 and AD rats received high, medium, and low doses of JDYZF orally for 8 weeks. The body weights of the AD rats were observed to assess the effect of JDYZF. The 16S rRNA sequencing technique was used to study the regulation of the gut microbiota by JDYZF in AD rats. Immunohistochemical staining was used to observe the expression levels of Caspase-1 and Caspase-11 in the hippocampus. Results. JDYZF reduced body weight in AD rats, and this effect may be related to JDYZF regulating body-weight-related gut microbes. The 16S rRNA analysis showed that JDYZF increased the diversity of the gut microbiota in AD rats. At the phylum level, JDYZF increased the abundances of Bacteroidota and Actinobacteriota and decreased the abundances of Firmicutes, Campilobacterota, and Desulfobacterota. At the genus level, the abundances of Lactobacillus, Prevotella, Bacteroides, Christensenellaceae_R-7_group, Rikenellaceae_RC9_gut_group, and Blautia were increased and the abundances of Lachnospiraceae-NK4A136-group, Anaerobiospirillum, Turicibacter, Oscillibacter, Desulfovibrio, Helicobacter, and Intestinimonas were decreased. At the species level, the abundances of Lactobacillus johnsonii, Lactobacillus reuteri, and Lactobacillus faecis were increased and the abundances of Helicobacter rodentium and Ruminococcus_sp_N15.MGS-57 were decreased. Immunohistochemistry showed that JDYZF reduced the levels of Caspase-1- and Caspase-11-positive staining. Conclusion. JDYZF has a regulatory effect on the gut microbiota of AD rats, which may represent the basis for the anti-inflammatory effect of JDYZF.
- Open Access
- 16 March 2022
- Published by Hindawi Limited in Evidence-Based Complementary and Alternative Medicine
- Vol. 2022, 1-14
Jiedu-Yizhi Formula Improves Cognitive Impairment in an Aβ25–35-Induced Rat Model of Alzheimer’s Disease by Inhibiting Pyroptosis
Jiedu-Yizhi formula (JDYZF) is prescribed for the treatment of Alzheimers disease (AD) and was created by Jixue Ren, a master of traditional Chinese medicine, based on the marrow deficiency and toxin damage theory. In our clinic, this formula has been used for the treatment of AD for many years and has achieved good results. However, the mechanism by which JDYZF improves cognitive impairment has not been determined. In this study, we confirmed that orally administered JDYZF reversed the cognitive deficits in an Aβ25–35-induced rat model, increased the number of neurons in the hippocampal CA1 area, improved their structure, decreased the deposition of β-amyloid (Aβ), reduced the expression of proteins related to the NLRP3/Caspase-1/GSDMD and LPS/Caspase-11/GSDMD pyroptosis pathways, and reduced the levels of interleukin 1β (IL-1β) and IL-18, thereby inhibiting the inflammatory response. In addition, JDYZF exerted no hepatotoxicity in rats. In short, these results provide scientific support for the clinical use of JDYZF to improve the cognitive function of patients with AD.
- 16 March 2022
- Published by Hindawi Limited in Evidence-Based Complementary and Alternative Medicine
- Vol. 2022, 1-14
Open AccessJiedu-Yizhi Formula Improves Cognitive Impairment in an Aβ25–35-Induced Rat Model of Alzheimer’s Disease by Inhibiting Pyroptosis
Jiedu-Yizhi formula (JDYZF) is prescribed for the treatment of Alzheimers disease (AD) and was created by Jixue Ren, a master of traditional Chinese medicine, based on the marrow deficiency and toxin damage theory. In our clinic, this formula has been used for the treatment of AD for many years and has achieved good results. However, the mechanism by which JDYZF improves cognitive impairment has not been determined. In this study, we confirmed that orally administered JDYZF reversed the cognitive deficits in an Aβ25–35-induced rat model, increased the number of neurons in the hippocampal CA1 area, improved their structure, decreased the deposition of β-amyloid (Aβ), reduced the expression of proteins related to the NLRP3/Caspase-1/GSDMD and LPS/Caspase-11/GSDMD pyroptosis pathways, and reduced the levels of interleukin 1β (IL-1β) and IL-18, thereby inhibiting the inflammatory response. In addition, JDYZF exerted no hepatotoxicity in rats. In short, these results provide scientific support for the clinical use of JDYZF to improve the cognitive function of patients with AD.